Cellectar Biosciences/$CLRB
Cellectar Biosciences shares are trading higher after the company completed a $6.9 million public offering.
24 hours ago·Lightyear AI
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Cellectar Biosciences
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Ticker
$CLRB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
11
ISIN
US15117F8804
Website
CLRB Metrics
BasicAdvanced
$8.6M
-
-$23.40
0.51
-
Price and volume
Market cap
$8.6M
Beta
0.51
52-week high
$10.19
52-week low
$4.36
Financial strength
Current ratio
2.474
Quick ratio
2.31
Long term debt to equity
4.008
Total debt to equity
4.923
Profitability
EBITDA (TTM)
-45.918
Effective tax rate (TTM)
-0.27%
Management effectiveness
Return on assets (TTM)
-97.91%
Return on equity (TTM)
-208.72%
Valuation
Price to book
0.94
Price to tangible book (TTM)
0.94
Price to free cash flow (TTM)
-0.147
Free cash flow yield (TTM)
-679.07%
Free cash flow per share (TTM)
-3,211.85%
Growth
Earnings per share change (TTM)
-79.01%
3-year earnings per share growth (CAGR)
-42.34%
CLRB News
AllArticlesVideos
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
GlobeNewsWire·2 days ago
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
GlobeNewsWire·3 days ago
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cellectar Biosciences stock?
Cellectar Biosciences (CLRB) has a market cap of $8.6M as of July 04, 2025.
What is the P/E ratio for Cellectar Biosciences stock?
The price to earnings (P/E) ratio for Cellectar Biosciences (CLRB) stock is 0 as of July 04, 2025.
Does Cellectar Biosciences stock pay dividends?
No, Cellectar Biosciences (CLRB) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Cellectar Biosciences dividend payment date?
Cellectar Biosciences (CLRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Cellectar Biosciences?
Cellectar Biosciences (CLRB) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.